Navigation Links
Verenium Announces $22.5 Million, Five-Year Secured Financing
Date:12/10/2012

SAN DIEGO, Dec. 10, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced the signing of a $22.5 million secured debt financing with the Athyrium Opportunities Fund ("Athyrium").

(Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO)

Net proceeds after estimated expenses will be approximately $21.3 million, providing Verenium with capital to continue to advance its Product Pipeline to commercialization, enhance its manufacturing capabilities, and fund general working capital purposes.  The debt bears interest at 11.5% per annum, with interest payments due quarterly over a five-year term and the principal balance due as a lump-sum payment at maturity in December 2017.

In connection with the financing, Verenium issued warrants to Athyrium to purchase approximately 2.9 million shares of common stock at an exercise price of $2.49 per share, representing a 17.5% premium over the closing price on the date of the debt agreement.  The warrants have a seven-year term and are immediately exercisable.

"We are pleased to be teaming with a long term strategic investor such as Athyrium in this transaction," said Jeffrey Black, Senior Vice President and Chief Financial Officer at Verenium.  "We anticipate that this financing will allow us to invest in our business and fund our growth initiatives through to operating profitability with minimal dilution to existing shareholders.  Importantly, with our financing needs now addressed, our management team can focus on unlocking the value in our business through new innovative products and partnerships."    

"Athyrium is excited to work with Verenium and its manage
'/>"/>

SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
2. Verenium to Present at Baird Clean Technology Conference
3. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
4. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
5. Verenium Corporation To Announce First Quarter 2012 Financial Results
6. Verenium Corporation Named One Of The 2012 Best Places to Work in San Diego
7. Verenium Corporation And Alexandria Real Estate Equities, Inc. Celebrate The Grand Opening Of A New State-of-the-art Biotechnology Facility
8. Verenium Announces EPA Authorization To Market Its Next-Generation Enzyme Breaker For Hydraulic Fracturing
9. Verenium Corporation To Announce Second Quarter 2012 Financial Results
10. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
11. Verenium Corporation To Announce Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... The "Bioinformatics Market By Sector (Molecular Medicine, ... & Data Analysis Services) & Application (Genomics, Proteomics & Drug ... Drivers, Restraints, and Opportunities in North America ... and Rest of World. Browse ... 22 Figures 364 Pages and an ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 This ... of pharmaceutical advertising and promotion, and review the ... will learn how to apply these principles through ... ,     The fundamentals on FDA regulations ... promotional labeling ,     Assessing traditional and newer ...
(Date:6/18/2013)... 2013   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... on discovering breakthrough treatments for human disease, announced ... the company as its vice president of marketing, ... commercial experience to Lexicon, including both pre-launch planning ... areas. Mr. Northcott has held commercial ...
(Date:6/18/2013)... Though health care jobs continued to ... Bureau of Labor Statistics -- the increase was far below ... new health care jobs were added in home health care ... of 6,000 jobs. Overall, the U.S. unemployment rate stayed flat ... Christmas reported that a total of just over 36,000 job ...
Breaking Biology Technology:Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3MedZilla Employment Report for June 2013 -- Jobs in Health Care Grow, But at Slower Pace 2MedZilla Employment Report for June 2013 -- Jobs in Health Care Grow, But at Slower Pace 3
... Institute at Cincinnati Children,s Hospital Medical Center have discovered a ... failure in some children and adults with dilated cardiomyopathy (DCM). ... is the most common cause of chronic heart failure in ... ANKRD1 is a gene that encodes a protein that plays ...
... CAMBRIDGE, Mass. (July 13, 2009) Whitehead Institute scientists ... be used to target diseases that until now have ... technique uses baker,s yeast to synthesize and screen the ... a matter of weeks. The current ...
... Yale University researchers has discovered a "repulsive" light force ... microchips, meaning future nanodevices could be controlled by light ... an "attractive" force of light and showed how it ... and nano-electrical systemstiny mechanical switches on a chip. The ...
Cached Biology Technology:Novel gene found for dilated cardiomyopathy 2New method may accelerate drug discovery for difficult diseases like Parkinson's 2New method may accelerate drug discovery for difficult diseases like Parkinson's 3New method may accelerate drug discovery for difficult diseases like Parkinson's 4Scientists discover repulsive side to light force 2
(Date:6/18/2013)... internationally recognized feline experts including veterinarians and feline scientists ... Lincoln, U.K. and Dr Ilona Rodan, Director of Cat ... Society of Feline Medicine (ISFM) and the American Association ... owners and those working with cats on how to ... new guidelines appear in the Journal of Feline ...
(Date:6/17/2013)... Boston, MA Women in the U.S. exposed to high ... as likely to have a child with autism as women ... new study from Harvard School of Public Health (HSPH). It ... autism and air pollution across the U.S. , "Our findings ... of the women in our study lived in areas where ...
(Date:6/17/2013)... a new virus in patients with severe brain infections ... the virus is responsible for the symptoms of disease. ... 28 out of 644 patients with severe brain infections ... in any of the 122 patients with non-infectious brain ... and central nervous system are often fatal and patients ...
Breaking Biology News(10 mins):Feline behavior experts release guidelines to improve the welfare of cats 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2New virus isolated from patients with severe brain infections 2New virus isolated from patients with severe brain infections 3
... University scientist Darla Goeres knows that there is more than one ... make sure that when a product claims it kills "99 percent" ... the extremely common communities of bacteria that form on most wet ... on streamside rocks to the sludge that clogs pipes. ...
... biochemists are now able to access 3D images ... than relying on text to provide the understanding ... now provides a new resource by linking written ... resource, first described in BioMed Central,s open access ...
... Researchers at Sheffield University and the University of St. Andrews, ... of information may or may not easily cause a recollection ... find, is in the way in which the learned information ... open-access journal PLoS Computational Biology . When one ...
Cached Biology News:MSU biofilms research helps set standards for everyday products 2